Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre André

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Nature Communications|September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancerPanagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
International Journal of Molecular Sciences|December 11, 2022
Fusion Cell Markers in Circulating Tumor Cells from Patients with High-Grade Ovarian Serous CarcinomaAnna Paula Carreta Ruano, Andrea Paiva Gadelha Guimarães, Alexcia C Braun, et al.
JCO Precision Oncology|April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker AnalysesPanagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Ecancermedicalscience|September 27, 2021
Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancerAdriana Regina Gonçalves Ribeiro, Marcella Marineli Salvadori, Louise de Brot, et al.
BMC Cancer|December 7, 2019
Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasisAlexandre André Balieiro Anastácio da Costa, Elizabeth Santana Dos Santos, Deborah Porto Cotrim, et al.
British Journal of Cancer|April 19, 2023
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2Denise G O'Mahony, Susan J Ramus, Melissa C Southey, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Nature Communications|September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancerPanagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
International Journal of Molecular Sciences|December 11, 2022
Fusion Cell Markers in Circulating Tumor Cells from Patients with High-Grade Ovarian Serous CarcinomaAnna Paula Carreta Ruano, Andrea Paiva Gadelha Guimarães, Alexcia C Braun, et al.
JCO Precision Oncology|April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker AnalysesPanagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Ecancermedicalscience|September 27, 2021
Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancerAdriana Regina Gonçalves Ribeiro, Marcella Marineli Salvadori, Louise de Brot, et al.
BMC Cancer|December 7, 2019
Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasisAlexandre André Balieiro Anastácio da Costa, Elizabeth Santana Dos Santos, Deborah Porto Cotrim, et al.
British Journal of Cancer|April 19, 2023
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2Denise G O'Mahony, Susan J Ramus, Melissa C Southey, et al.
Pageof 3